UY37334A - Compuesto, procedimiento de obtención del compuesto, composición farmacéutica, uso del compuesto y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño - Google Patents
Compuesto, procedimiento de obtención del compuesto, composición farmacéutica, uso del compuesto y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueñoInfo
- Publication number
- UY37334A UY37334A UY0001037334A UY37334A UY37334A UY 37334 A UY37334 A UY 37334A UY 0001037334 A UY0001037334 A UY 0001037334A UY 37334 A UY37334 A UY 37334A UY 37334 A UY37334 A UY 37334A
- Authority
- UY
- Uruguay
- Prior art keywords
- compound
- disorders
- treatment
- procedure
- obtaining
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- 208000019116 sleep disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 abstract 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 1
- 102100024930 Melatonin receptor type 1A Human genes 0.000 abstract 1
- 101710098568 Melatonin receptor type 1A Proteins 0.000 abstract 1
- 102100024970 Melatonin receptor type 1B Human genes 0.000 abstract 1
- 101710098567 Melatonin receptor type 1B Proteins 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- -1 benzimidazole derivative compounds Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000002060 circadian Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003987 melatonin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UY0001040644A UY40644A (es) | 2016-10-24 | 2017-07-19 | Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102016024814A BR102016024814A2 (pt) | 2016-10-24 | 2016-10-24 | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37334A true UY37334A (es) | 2018-04-30 |
Family
ID=62023150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037334A UY37334A (es) | 2016-10-24 | 2017-07-19 | Compuesto, procedimiento de obtención del compuesto, composición farmacéutica, uso del compuesto y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |
| UY0001040644A UY40644A (es) | 2016-10-24 | 2017-07-19 | Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001040644A UY40644A (es) | 2016-10-24 | 2017-07-19 | Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10781182B2 (https=) |
| EP (2) | EP3529234B1 (https=) |
| JP (1) | JP7194683B2 (https=) |
| KR (1) | KR102594251B1 (https=) |
| CN (2) | CN115181108A (https=) |
| AR (1) | AR109467A1 (https=) |
| AU (1) | AU2017351756B2 (https=) |
| BR (1) | BR102016024814A2 (https=) |
| CL (1) | CL2019001105A1 (https=) |
| CO (1) | CO2019004756A2 (https=) |
| DK (1) | DK3529234T3 (https=) |
| EC (1) | ECSP19032963A (https=) |
| ES (2) | ES2970546T3 (https=) |
| FI (1) | FI3529234T3 (https=) |
| MX (1) | MX392990B (https=) |
| PE (2) | PE20250558A1 (https=) |
| PT (1) | PT3529234T (https=) |
| SG (2) | SG10202009001TA (https=) |
| UY (2) | UY37334A (https=) |
| WO (1) | WO2018076090A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| EP3640251B1 (en) | 2016-10-24 | 2021-12-08 | Astrazeneca AB | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| PL3494116T3 (pl) | 2017-01-30 | 2020-04-30 | Astrazeneca Ab | Modulatory receptora estrogenowego |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
| MX2022013391A (es) | 2020-04-24 | 2022-11-30 | Astrazeneca Ab | Pauta posologica para el tratamiento del cancer. |
| MX2022013258A (es) | 2020-04-24 | 2022-11-14 | Astrazeneca Ab | Formulaciones farmaceuticas. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5260051A (en) | 1990-12-17 | 1993-11-09 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions comprising phosphate ester compounds containing a beneficial reagent component |
| FR2674524B1 (fr) | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2680366B1 (fr) * | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| JP3559045B2 (ja) * | 1994-06-10 | 2004-08-25 | ナウチノ−イススレドバテルスキ インスティテュト ファルマコロギイ ロスシイスコイ アカデミイ メディツィンスキフ ナウク | 薬理学的活性を有する２−メルカプトベンズイミダゾール誘導体 |
| US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| FR2738818B1 (fr) | 1995-09-18 | 1997-12-05 | Valentonine | Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament |
| JP2884153B2 (ja) * | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
| US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| RU2190609C2 (ru) | 1996-12-10 | 2002-10-10 | Бристол-Маерс Сквибб Компани | Производные бензодиоксола, бензофурана, дигидробензофурана и бензодиоксана и содержащие их композиции |
| US6214869B1 (en) | 1998-06-05 | 2001-04-10 | Bristol-Myers Squibb | Heterocyclic cis cyclopropane derivatives as melatonergic agents |
| DE60007745T2 (de) | 1999-06-30 | 2005-03-10 | Bristol-Myers Squibb Co. | Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe |
| US7408067B2 (en) | 2002-01-17 | 2008-08-05 | Merck + Co., Inc. | Aza-cyclic compounds as modulators of acetylcholine receptors |
| CN1922141A (zh) * | 2004-02-23 | 2007-02-28 | 大日本住友制药株式会社 | 新的杂环化合物 |
| ES2264641B1 (es) * | 2005-06-17 | 2008-03-01 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios. |
| US20090298811A1 (en) * | 2006-09-12 | 2009-12-03 | Pfizer Inc | Benzimidazolone derivatives |
| US20100056515A1 (en) * | 2006-10-25 | 2010-03-04 | Kazuyoshi Aso | Benzimidazole compounds |
| RU2401831C2 (ru) * | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
-
2016
- 2016-10-24 BR BR102016024814A patent/BR102016024814A2/pt not_active Application Discontinuation
-
2017
- 2017-07-19 UY UY0001037334A patent/UY37334A/es active IP Right Grant
- 2017-07-19 UY UY0001040644A patent/UY40644A/es not_active Application Discontinuation
- 2017-08-30 AR ARP170102402A patent/AR109467A1/es active IP Right Grant
- 2017-10-23 KR KR1020197011842A patent/KR102594251B1/ko active Active
- 2017-10-23 SG SG10202009001TA patent/SG10202009001TA/en unknown
- 2017-10-23 AU AU2017351756A patent/AU2017351756B2/en active Active
- 2017-10-23 MX MX2019004782A patent/MX392990B/es unknown
- 2017-10-23 CN CN202210815568.3A patent/CN115181108A/zh active Pending
- 2017-10-23 SG SG11201903113TA patent/SG11201903113TA/en unknown
- 2017-10-23 EP EP17865155.0A patent/EP3529234B1/en active Active
- 2017-10-23 PE PE2023002494A patent/PE20250558A1/es unknown
- 2017-10-23 ES ES17865155T patent/ES2970546T3/es active Active
- 2017-10-23 ES ES20185268T patent/ES3013994T3/es active Active
- 2017-10-23 CN CN201780079647.XA patent/CN110088092B/zh active Active
- 2017-10-23 EP EP20185268.8A patent/EP3741760B1/en active Active
- 2017-10-23 PT PT178651550T patent/PT3529234T/pt unknown
- 2017-10-23 JP JP2019542758A patent/JP7194683B2/ja active Active
- 2017-10-23 PE PE2019000861A patent/PE20191046A1/es unknown
- 2017-10-23 US US16/344,721 patent/US10781182B2/en active Active
- 2017-10-23 FI FIEP17865155.0T patent/FI3529234T3/fi active
- 2017-10-23 DK DK17865155.0T patent/DK3529234T3/da active
- 2017-10-23 WO PCT/BR2017/050320 patent/WO2018076090A1/en not_active Ceased
-
2019
- 2019-04-23 CL CL2019001105A patent/CL2019001105A1/es unknown
- 2019-05-09 EC ECSENADI201932963A patent/ECSP19032963A/es unknown
- 2019-05-09 CO CONC2019/0004756A patent/CO2019004756A2/es unknown
-
2020
- 2020-05-13 US US15/930,990 patent/US11091445B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004756A2 (es) | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño | |
| CL2020003425A1 (es) | Nuevos derivados heterocíclicos útiles como inhibidores de shp2 (divisional solicitud n° 201902698) | |
| MX2019010539A (es) | Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak. | |
| MX2013006634A (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. | |
| ECSP11010885A (es) | Heteroarilos sustituidos | |
| EA201071057A1 (ru) | Производные азетидина и циклобутана как ингибиторы jak-киназ | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| PE20190181A1 (es) | Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| EA200701588A1 (ru) | Способы получения замещённых фенилпиразолмочевин | |
| EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
| MX383124B (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| CY1125323T1 (el) | ΚΥΚΛΙΚΑ ΠΑΡΑΓΩΓΑ ΑΙΘΕΡΑ ΤΟΥ ΠΥΡΑΖOΛO[1,5- a]ΠΥΡΙΜΙΔΙΝO-3-ΚΑΡΒOΞΥΑΜΙΔΙOΥ | |
| EA201000675A1 (ru) | Производные хромана как модуляторы trpv3 | |
| EA201990362A1 (ru) | Аналог вортиоксетина и его применение и получение | |
| MX2018012840A (es) | Compuestos heterociclicos biciclicos sustituidos. | |
| NZ720879A (en) | Indazole compounds as 5-ht4 receptor agonists | |
| MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. | |
| CL2012001601A1 (es) | Compuestos derivados de tiazoles biciclicos, composición farmacéutica; proceso para preparar la composición farmacéutica; kit farmacéutico que los comprende; y su uso en la prevención o tratamiento de enfermedades en las cuales el efecto neuromodulador de los moduladores alostericos de mglur5 es beneficioso. | |
| CY1110087T1 (el) | Μεθοδοι παρασκευης ενωσεων που περιεχουν πυρραζολιο | |
| EA201190003A1 (ru) | Производные хроменона в качестве trpv3 антагонистов | |
| JOP20230029A1 (ar) | مشتقات كيمرين-9 حلقي | |
| UY32447A (es) | Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia | |
| MX2019000276A (es) | Nuevos derivados ciclopropílicos. | |
| GEAP202416522A (en) | Process for preparing bicyclic glycine-proline compounds and monocyclic glycine-proline intermediates thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 110 | Patent granted |
Effective date: 20240911 |